In advanced NSCLC, anlotinib is a small molecule multi-target tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1–3 (VEGFR1–3), fibroblast growth factor receptor 1–4 (FGFR1–4), and platelet-derived growth factor receptor α-β (PDGFRα-β), among others [18, 19]. Here, FLT1 is linked to non-small cell lung carcinoma.